Drug giants Merck & Co and Schering-
Plough have announced plans to
merge in a $41.1bn deal – just one
in a spate of mega-mergers so far
this year. Under pressure to increase
revenues, large pharmaceutical firms
are seeking scale, resources and
diversified portfolios less vulnerable
to generic competition. While Q1
2009 has seen colossal deals, future
consolidation is expected to be
smaller and more strategic.
It is 10 years since the Control of Major
Accident Hazards (COMAH) regulations came
into force, with the aim of preventing and
mitigating the effects of major accidents
involving dangerous substances. So what have
we learnt since 1999, what has changed over
the recent past, and what effect will these
regulations have in the future? Incidents such
as BP Texas City in March 2005, where 15
people were killed and a further 180 injured,
and Buncefield, have led safety experts to
review what value the COMAH regulations
give and how they are implemented in the
Is uncorking headed for the dustbin?
The webinar begins by asking the question “Why is the Earth’s surface the temperature it is?”.
With the ever increasing change in the global economic demographics it is time to consider just what impact this has beyond the already accepted increase in healthcare costs.
presented on 19 Nov 2013
Poster by Dr. Alessandro Poma, Dr. Yao Xu and Dr. Nicholas Turner
Poster by Zheling Li, Robert J. Young and Ian A. Kinloch
Poster by Victoria J. Wickens, Mike P. Garratt, Alison P. Bailey and Simon G. Potts
Poster by Jennifer Wickens, Stuart Roberts, Alison Bailey and Simon G. Potts
Poster by Nicholas J. Race and Dr. John F. Bower
Poster by Callie Seaman, Bryn Flinders and Malcolm Clench
There are no postcards for the issue of C&I Magazine which you have selected.
Click here to see other postcards from our international correspondents.
When the global economic situation changes as rapidly
as it has over the last few months, real statistics can be
very hard to come by. Certainly the reported financial
performance of companies for Q4 2008 gives a shocking
picture of plummeting demand, and some have given an
indication in overall volume terms of the scale of that rapid
decline in fortunes (C&I 2009, 4, 5; 5, 6).
Is arsenic an aphrodisiac? The answer
is no. Did people once think it was?
The answer is yes. But this oddly
titled book is not about sex, it’s about
living and dying, and it answers much
more interesting questions, including
seemingly conflicting ones: ‘Is arsenic
a cause of cancer?’ and ‘Is arsenic a
cure for cancer?’ In both cases the
answer is yes. Which sums up the
duality of one of the most puzzling
elements of the periodic table.
Subscribe to C&I Newsletter